Strengthening Africa’s Medicines Regulatory Framework is ‘Essential’ for Local Vaccine Production 13/09/2023 Kerry Cullinan Strengthening Africa’s medicines regulatory framework is key to achieving the “bold goal” of having 60% of the continent’s vaccines produced locally by 2040, said Margareth Ndomondo-Sigonda, head of health at the African Union’s development agency, AUDA-NEPAD. But only 7% of African country’s national medicines regulatory agencies (NMRA) have “moderately developed capacity”, and more than 90% […] Continue reading -> UN Draft Pandemic Declaration Offers ‘Little Hope’ for Strengthening Global Preparedness 01/09/2023 Stefan Anderson A draft political declaration on pandemics, due to be adopted by the United Nations General Assembly later this month, offers “little hope” that the UN process will make a difference in global pandemic preparedness, global health experts said on Friday. The document, made public on Thursday, is long on words but short on commitments. The […] Continue reading -> WHO Secures First COVID-19 Vaccine Licence from Private Pharmaceutical Company 31/08/2023 Stefan Anderson Three years after the launch of its COVID-19 Technology Access Pool (C-TAP) initiative, the World Health Organization (WHO) has secured its first COVID-19 vaccine license from a private pharmaceutical company, the UN health body announced on Tuesday. The agreement with Medigen Vaccine Biologics Corp., a private vaccine manufacturer based in Taiwan, is a welcome but underwhelming […] Continue reading -> Africa’s Cardiovascular Burden: A Silent Cry for Attention 23/08/2023 Ahmed Bendary & Abdelrahman Abushouk Amidst the vibrant rhythms of Africa, a less audible rhythm beats – an alarming rise in cardiovascular diseases (CVDs) and non-communicable diseases (NCDs). Between 50% and 88% of deaths in at least seven African countries are due to NCDs, according to the 2022 World Health Organization (WHO) Noncommunicable Disease Progress Monitor. Yet, the realm of […] Continue reading -> Brazil’s Success in Preventing Malaria Relapse Using New Single-Dose Treatment 20/07/2023 Marcus Lacerda & Elodie Jambert Brazil is the first country in the world to introduce tafenoquine, the first new single-dose treatment for P. vivax malaria developed in 70 years, in its public health system. Raquel da Silva has lived in Manaus in Brazil’s Amazonas State since her childhood. Today she shares her home on the banks of the Rio Negro […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Contestation About Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> New ‘Lab’ Aims to Leverage Digital Tools for Health Policy Making 03/06/2023 Maayan Hoffman A new collaboration called the “Global Health Policy Lab” (GHPL) aims to develop digital tools that strengthen the available global capacity to identify, benchmark, disseminate and assess the impact of relevant health laws and policies within the field of global health. The lab, a partnership between the Harvard Health Systems Innovation Lab and the Charité […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> US FDA Approves First-Ever RSV Vaccine 04/05/2023 Megha Kaveri The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
UN Draft Pandemic Declaration Offers ‘Little Hope’ for Strengthening Global Preparedness 01/09/2023 Stefan Anderson A draft political declaration on pandemics, due to be adopted by the United Nations General Assembly later this month, offers “little hope” that the UN process will make a difference in global pandemic preparedness, global health experts said on Friday. The document, made public on Thursday, is long on words but short on commitments. The […] Continue reading -> WHO Secures First COVID-19 Vaccine Licence from Private Pharmaceutical Company 31/08/2023 Stefan Anderson Three years after the launch of its COVID-19 Technology Access Pool (C-TAP) initiative, the World Health Organization (WHO) has secured its first COVID-19 vaccine license from a private pharmaceutical company, the UN health body announced on Tuesday. The agreement with Medigen Vaccine Biologics Corp., a private vaccine manufacturer based in Taiwan, is a welcome but underwhelming […] Continue reading -> Africa’s Cardiovascular Burden: A Silent Cry for Attention 23/08/2023 Ahmed Bendary & Abdelrahman Abushouk Amidst the vibrant rhythms of Africa, a less audible rhythm beats – an alarming rise in cardiovascular diseases (CVDs) and non-communicable diseases (NCDs). Between 50% and 88% of deaths in at least seven African countries are due to NCDs, according to the 2022 World Health Organization (WHO) Noncommunicable Disease Progress Monitor. Yet, the realm of […] Continue reading -> Brazil’s Success in Preventing Malaria Relapse Using New Single-Dose Treatment 20/07/2023 Marcus Lacerda & Elodie Jambert Brazil is the first country in the world to introduce tafenoquine, the first new single-dose treatment for P. vivax malaria developed in 70 years, in its public health system. Raquel da Silva has lived in Manaus in Brazil’s Amazonas State since her childhood. Today she shares her home on the banks of the Rio Negro […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Contestation About Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> New ‘Lab’ Aims to Leverage Digital Tools for Health Policy Making 03/06/2023 Maayan Hoffman A new collaboration called the “Global Health Policy Lab” (GHPL) aims to develop digital tools that strengthen the available global capacity to identify, benchmark, disseminate and assess the impact of relevant health laws and policies within the field of global health. The lab, a partnership between the Harvard Health Systems Innovation Lab and the Charité […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> US FDA Approves First-Ever RSV Vaccine 04/05/2023 Megha Kaveri The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Secures First COVID-19 Vaccine Licence from Private Pharmaceutical Company 31/08/2023 Stefan Anderson Three years after the launch of its COVID-19 Technology Access Pool (C-TAP) initiative, the World Health Organization (WHO) has secured its first COVID-19 vaccine license from a private pharmaceutical company, the UN health body announced on Tuesday. The agreement with Medigen Vaccine Biologics Corp., a private vaccine manufacturer based in Taiwan, is a welcome but underwhelming […] Continue reading -> Africa’s Cardiovascular Burden: A Silent Cry for Attention 23/08/2023 Ahmed Bendary & Abdelrahman Abushouk Amidst the vibrant rhythms of Africa, a less audible rhythm beats – an alarming rise in cardiovascular diseases (CVDs) and non-communicable diseases (NCDs). Between 50% and 88% of deaths in at least seven African countries are due to NCDs, according to the 2022 World Health Organization (WHO) Noncommunicable Disease Progress Monitor. Yet, the realm of […] Continue reading -> Brazil’s Success in Preventing Malaria Relapse Using New Single-Dose Treatment 20/07/2023 Marcus Lacerda & Elodie Jambert Brazil is the first country in the world to introduce tafenoquine, the first new single-dose treatment for P. vivax malaria developed in 70 years, in its public health system. Raquel da Silva has lived in Manaus in Brazil’s Amazonas State since her childhood. Today she shares her home on the banks of the Rio Negro […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Contestation About Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> New ‘Lab’ Aims to Leverage Digital Tools for Health Policy Making 03/06/2023 Maayan Hoffman A new collaboration called the “Global Health Policy Lab” (GHPL) aims to develop digital tools that strengthen the available global capacity to identify, benchmark, disseminate and assess the impact of relevant health laws and policies within the field of global health. The lab, a partnership between the Harvard Health Systems Innovation Lab and the Charité […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> US FDA Approves First-Ever RSV Vaccine 04/05/2023 Megha Kaveri The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Africa’s Cardiovascular Burden: A Silent Cry for Attention 23/08/2023 Ahmed Bendary & Abdelrahman Abushouk Amidst the vibrant rhythms of Africa, a less audible rhythm beats – an alarming rise in cardiovascular diseases (CVDs) and non-communicable diseases (NCDs). Between 50% and 88% of deaths in at least seven African countries are due to NCDs, according to the 2022 World Health Organization (WHO) Noncommunicable Disease Progress Monitor. Yet, the realm of […] Continue reading -> Brazil’s Success in Preventing Malaria Relapse Using New Single-Dose Treatment 20/07/2023 Marcus Lacerda & Elodie Jambert Brazil is the first country in the world to introduce tafenoquine, the first new single-dose treatment for P. vivax malaria developed in 70 years, in its public health system. Raquel da Silva has lived in Manaus in Brazil’s Amazonas State since her childhood. Today she shares her home on the banks of the Rio Negro […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Contestation About Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> New ‘Lab’ Aims to Leverage Digital Tools for Health Policy Making 03/06/2023 Maayan Hoffman A new collaboration called the “Global Health Policy Lab” (GHPL) aims to develop digital tools that strengthen the available global capacity to identify, benchmark, disseminate and assess the impact of relevant health laws and policies within the field of global health. The lab, a partnership between the Harvard Health Systems Innovation Lab and the Charité […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> US FDA Approves First-Ever RSV Vaccine 04/05/2023 Megha Kaveri The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Brazil’s Success in Preventing Malaria Relapse Using New Single-Dose Treatment 20/07/2023 Marcus Lacerda & Elodie Jambert Brazil is the first country in the world to introduce tafenoquine, the first new single-dose treatment for P. vivax malaria developed in 70 years, in its public health system. Raquel da Silva has lived in Manaus in Brazil’s Amazonas State since her childhood. Today she shares her home on the banks of the Rio Negro […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Contestation About Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> New ‘Lab’ Aims to Leverage Digital Tools for Health Policy Making 03/06/2023 Maayan Hoffman A new collaboration called the “Global Health Policy Lab” (GHPL) aims to develop digital tools that strengthen the available global capacity to identify, benchmark, disseminate and assess the impact of relevant health laws and policies within the field of global health. The lab, a partnership between the Harvard Health Systems Innovation Lab and the Charité […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> US FDA Approves First-Ever RSV Vaccine 04/05/2023 Megha Kaveri The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Contestation About Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> New ‘Lab’ Aims to Leverage Digital Tools for Health Policy Making 03/06/2023 Maayan Hoffman A new collaboration called the “Global Health Policy Lab” (GHPL) aims to develop digital tools that strengthen the available global capacity to identify, benchmark, disseminate and assess the impact of relevant health laws and policies within the field of global health. The lab, a partnership between the Harvard Health Systems Innovation Lab and the Charité […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> US FDA Approves First-Ever RSV Vaccine 04/05/2023 Megha Kaveri The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Contestation About Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> New ‘Lab’ Aims to Leverage Digital Tools for Health Policy Making 03/06/2023 Maayan Hoffman A new collaboration called the “Global Health Policy Lab” (GHPL) aims to develop digital tools that strengthen the available global capacity to identify, benchmark, disseminate and assess the impact of relevant health laws and policies within the field of global health. The lab, a partnership between the Harvard Health Systems Innovation Lab and the Charité […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> US FDA Approves First-Ever RSV Vaccine 04/05/2023 Megha Kaveri The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
New ‘Lab’ Aims to Leverage Digital Tools for Health Policy Making 03/06/2023 Maayan Hoffman A new collaboration called the “Global Health Policy Lab” (GHPL) aims to develop digital tools that strengthen the available global capacity to identify, benchmark, disseminate and assess the impact of relevant health laws and policies within the field of global health. The lab, a partnership between the Harvard Health Systems Innovation Lab and the Charité […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> US FDA Approves First-Ever RSV Vaccine 04/05/2023 Megha Kaveri The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> US FDA Approves First-Ever RSV Vaccine 04/05/2023 Megha Kaveri The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
US FDA Approves First-Ever RSV Vaccine 04/05/2023 Megha Kaveri The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading -> Posts navigation Older posts